Pharmaceutical manufacturing, quality, and supply chain management can all benefit from the wise application of artificial intelligence (AI). But what approach should pharma manufacturers take to harnessing AI in these areas? And what are the risks?

To explore these questions, we sat down with Pat Day, a principal consultant at Lachman Consultants. Following more than 25 years working inside the pharmaceutical industry, Pat now serves as a consultant, focusing on areas such as risk management, data integrity and data governance, and supply chain logistics — and now, AI.

We discussed:

• Where AI can offer the most immediate benefits in pharmaceutical manufacturing and quality
• The common mistake corporate leaders make in AI initiatives — and the risks that result (hint: protect your institutional knowledge)

• The value of AI “sprints”

• Why companies should approach AI projects as experiments — that are allowed to fail

• What the regulators are saying so far, and why industry shouldn’t wait for agency “permission”

• The opportunity to use AI to develop data skills in quality and regulatory teams

Given all he has seen, Pat offers his advice for rethinking ROI for AI in pharma manufacturing and quality and suggests best practices for thoughtful implementation.

Learn more & connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Pat Day: LinkedIn

• Learn more about Lachman Consultants

• Connect with our podcast host, Laura Bush: LinkedIn

B2B science marketing is changing, and yet certain fundamentals remain the same. How should life sciences companies plan and execute their marketing campaigns today? To explore that question, we sat down with Debra Harrsch, CEO of Brandwidth Solutions, and Peter Harrsch, PhD, Brandwidth’s chief science officer. Reflecting on what they have seen and learned since the agency’s founding 20 years ago, they discuss:

• What has changed the most in B2B science marketing, and what has remained constant, despite all the changes

• Where companies need to convey their message in today’s crowded markets

• The role of AI and GEO

• Why live interviews still matter

• How to measure results effectively

Debra and Peter share their insights, their forecasts for the next few years in science marketing, and some advice — including the importance of work team culture and a few tips for startups — from a company founder who knows firsthand both the excitement and perils of launching and growing a company.

Learn more & connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guests, Debra Harrsch (LinkedIn) and Peter Harrsch (LinkedIn)

• Check out Debra Harrsch’s roundtable at CPHI Worldwide: Navigating Growth: Lessons from the Startup Journey

• Connect with our podcast host, Meg Sizemore: LinkedIn

For B2B companies serving customers in the life sciences — in areas such as bio/pharmaceutical CDMO services, diagnostics, life sciences instrumentation, and laboratory software — creating and maintaining an engaging website is a challenging undertaking. Potential customers are smart and highly educated, and need a sufficient level of detail to inform their buyer’s journey. But they are also busy, impatient, and don’t have time to waste.

So how can life sciences companies optimize their websites and web content to attract and retain the interest of their potential buyers? To explore the nuances of this question, we sat down with Stephanie Fox. Stephanie Fox has been a website user experience (UX) practitioner for more than 25 years, and she recently published a book on this topic, called, Would You Date Your Website?

We discussed:

• The must-haves of user experience (UX) for technical B2B online spaces

• What “scannable” content looks like for scientific and technical audiences today

• How content and webpage design impact trust

• The most overlooked aspects of user experience (UX)

• How artificial intelligence (AI) is affecting user experience

Stephanie offers advice and wisdom, based on her decades of expertise, for ensuring optimal user experience on any B2B website for the life sciences industry.

Learn more & connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Stephanie Fox, on LinkedIn

• Check out Stephanie’s book: Would You Date Your Website?

• Connect with our podcast host, Meg Sizemore: LinkedIn

The U.S. administration is pushing for the onshoring of pharmaceutical production. But is there a sufficient supply of qualified people to staff expanded bioprocessing operations?

To explore that question, we sit down with Eric Langer, the president and managing partner of BioPlan Associates. For more than 20 years, his firm has been publishing the Annual Report of Biopharmaceutical Manufacturing Capacity and Production, so he has the data to back up his views.

We discussed:

• The current state of bioprocessing hiring and long-term trends

• The situation at CDMOs compared to innovator companies

• The impact of geopolitics, including changes to H-1B visa rules

• Job-seekers’ emotional reactions to the current climate

• The staff training gap for expanding manufacturing operations

Eric shares his assessment, putting it all into context—considering both current events and more than 20 years of data.

Learn more & connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Eric Langer: LinkedIn

• Check out the 22nd Annual Report of Biopharmaceutical Manufacturing Capacity and Production

• Connect with our podcast host, Laura Bush: LinkedIn

On August 16, the administration issued an executive order to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The plan begins by stockpiling a six-month supply of 26 critical drugs, with the goal of expanding to a list of 86 essential medicines. What does this mean for pharmaceutical manufacturing, contract development and manufacturing organizations (CDMOs), and the broader drug supply chain?

In this episode of BWS Dialogues, we sit down with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA), to unpack the implications of this initiative. Gil shares insights and offers a candid look at the opportunities, challenges, and unintended consequences.

We explore questions such as:

• How does this plan build on—and differ from—previous U.S. drug stockpiling efforts?

• What short- and long-term impacts could this initiative have on pharmaceutical manufacturing and the CDMO sector?

• How effective are other recent measures, like accelerated FDA plant approvals, the PreCheck program, and EQUIP-A-Pharma in supporting U.S.-based drug manufacturing?

• How would pharmaceutical tariffs affect innovators, generics companies, and CDMOs?

• What other factors need to be considered to make reshoring efforts work?

Gil offers his perspectives on how these programs intersect, what gaps remain, and what it will take to build a more resilient pharmaceutical supply chain in the United States.

Learn More & Connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Gil Roth: LinkedIn

• Connect with our podcast host, Laura Bush: LinkedIn